Recursion Pharmaceuticals Statistics

Total Valuation

RXRX has a market cap or net worth of $2.23 billion. The enterprise value is $1.83 billion.

Market Cap	2.23B
Enterprise Value	1.83B

Important Dates

The last earnings date was Monday, May 5, 2025, before market open.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

RXRX has 406.92 million shares outstanding. The number of shares has increased by 44.28% in one year.

Current Share Class	399.66M
Shares Outstanding	406.92M
Shares Change (YoY)	+44.28%
Shares Change (QoQ)	+19.86%
Owned by Insiders (%)	4.40%
Owned by Institutions (%)	72.61%
Float	388.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.01
Forward PS	39.77
PB Ratio	2.39
P/TBV Ratio	5.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	30.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.10.

Current Ratio	4.11
Quick Ratio	3.85
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-278.66

Financial Efficiency

Return on equity (ROE) is -86.10% and return on invested capital (ROIC) is -48.52%.

Return on Equity (ROE)	-86.10%
Return on Assets (ROA)	-38.51%
Return on Invested Capital (ROIC)	-48.52%
Return on Capital Employed (ROCE)	-49.35%
Revenue Per Employee	$74,738
Profits Per Employee	-$718,469
Employee Count	800
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	-506,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.60% in the last 52 weeks. The beta is 0.83, so RXRX's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-39.60%
50-Day Moving Average	4.89
200-Day Moving Average	6.47
Relative Strength Index (RSI)	61.38
Average Volume (20 Days)	23,231,521

Short Selling Information

The latest short interest is 104.22 million, so 25.61% of the outstanding shares have been sold short.

Short Interest	104.22M
Short Previous Month	93.12M
Short % of Shares Out	25.61%
Short % of Float	26.82%
Short Ratio (days to cover)	5.63

Income Statement

In the last 12 months, RXRX had revenue of $59.79 million and -$574.78 million in losses. Loss per share was -$1.82.

Revenue	59.79M
Gross Profit	-372.61M
Operating Income	-574.03M
Pretax Income	n/a
Net Income	-574.78M
EBITDA	-525.58M
EBIT	-574.03M
Loss Per Share	-$1.82

Full Income Statement

Balance Sheet

The company has $500.45 million in cash and $92.91 million in debt, giving a net cash position of $407.54 million or $1.00 per share.

Cash & Cash Equivalents	500.45M
Total Debt	92.91M
Net Cash	407.54M
Net Cash Per Share	$1.00
Equity (Book Value)	933.95M
Book Value Per Share	2.30
Working Capital	442.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$388.83 million and capital expenditures -$8.87 million, giving a free cash flow of -$397.71 million.

Operating Cash Flow	-388.83M
Capital Expenditures	-8.87M
Free Cash Flow	-397.71M
FCF Per Share	-$0.98

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-960.08%
Pretax Margin	-962.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RXRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-44.28%
Shareholder Yield	-44.28%
Earnings Yield	-25.73%
FCF Yield	-17.80%

Dividend Details

Analyst Forecast

The average price target for RXRX is $7.60, which is 38.43% higher than the current price. The consensus rating is "Buy".

Price Target	$7.60
Price Target Difference	38.43%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RXRX has an Altman Z-Score of 0.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.86
Piotroski F-Score	1